Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids in OCD
NCT03274440Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Countries
- 1
- Sponsor
- New York State Psychiatric Institute
- Modality
- Small Molecules
- Drugs
- cannabis
- Conditions
- obsessive compulsive disorder (OCD)
01
Overview
Phase 2, randomised, double-blind trial of cannabis in obsessive compulsive disorder (OCD) (3 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Yale-Brown Obsessive-Compulsive Challenge Scale at 180 months. Started Oct 2017; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
High THC/Low CBD
Marijuana with 5-10% THC and <1% CBD
Low THC/High CBD
Marijuana with <1% THC and >10% CBD
Placebo
No THC/No CBD Marijuana
03
Who it enrols
Adults aged 21-55 with OCD who are current marijuana users but not seeking substance abuse treatment. Excludes those with severe depression, other psychiatric disorders, or positive urine toxicology for drugs other than THC.
04
Endpoints
Primary
Yale-Brown Obsessive-Compulsive Challenge Scale
Secondary
Spielberger State-Trait Anxiety Scale: State Version
Beyond the preview
Go deeper on NCT03274440.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274440.